13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001263508
Total reported value
$20.0B
$20.0B
89 檔
30.5%
At the close of Q1 2025, Baker Bros. Advisors LP disclosed equity holdings valued at approximately $20.0B, spread across 89 reported holdings.
Baker Bros. Advisors LP executed strategic sector rebalancing during Q1 2025, establishing 58 new positions while fully exiting 89 holdings and trimming 7 positions.
In terms of portfolio concentration, the top 5 core holdings (including ONC, INCY, ACAD) accounted for 30.5% of total reported equity market value during Q1 2025.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ONC | Beone Medicines Ltd-adr | Stock-Other | 26.50% | -2.43% | -7.69% | |
| 2 | INCY | Incyte CORP | Stock-Healthcare | 20.60% | +0.86% | +0.00% | |
| 3 | ACAD | Acadia Pharmaceuticals Inc | Stock-Healthcare | 7.88% | -0.04% | — | |
| 4 | MDGL | Madrigal Pharmaceuticals Inc | Stock-Healthcare | 7.24% | -0.67% | — | |
| 5 | SMMT | Summit Therapeutics Inc | Stock-Other | 5.21% | -1.57% | — | |
| 6 | INSM | Insmed Inc | Stock-Healthcare | 4.54% | -2.27% | +7.46% | |
| 7 | RYTM | Rhythm Pharmaceuticals Inc | Stock-Other | 3.29% | +0.32% | -7.89% | |
| 8 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 3.11% | +5.40% | — | |
| 9 | KYMR | Kymera Therapeutics Inc | Stock-Other | 1.82% | +0.83% | — | |
| 10 | ALKS | Alkermes plc | Stock-Healthcare | 1.64% | +0.60% | +7.21% | |
| 11 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 1.50% | -0.44% | — | |
| 12 | REPL | Replimune Group Inc | Stock-Other | 1.19% | +0.12% | — | |
| 13 | INSM 0.75 06-01-28Bond | Insmed Inc | Bond | 1.12% | — | — | |
| 14 | IMVT | Immunovant Inc | Stock-Other | 1.03% | +0.27% | +219.57% | |
| 15 | BCYC | Bicycle Therapeutics Plc-adr | Stock-Other | 1.02% | -0.06% | — | |
| 16 | IMCR | Immunocore Holdings Plc-adr | Stock-Other | 0.76% | -0.13% | EXIT | |
| 17 | KNSA | Kiniksa Pharmaceuticals International, plc | Stock-Other | 0.69% | +0.13% | — | |
| 18 | ABCL | Abcellera Biologics Inc | Stock-Other | 0.68% | +0.69% | — | |
| 19 | RARE | Ultragenyx Pharmaceutical In | Stock-Other | 0.63% | — | — | |
| 20 | DNLI | Denali Therapeutics Inc | Stock-Other | 0.56% | +0.07% | — | |
| 21 | KOD | Kodiak Sciences Inc | Stock-Other | 0.54% | -0.47% | — | |
| 22 | NRIX | Nurix Therapeutics Inc | Stock-Other | 0.51% | +0.16% | — | |
| 23 | ARGX | Argenx Se - Adr | Stock-Healthcare | 0.51% | -0.11% | EXIT | |
| 24 | TRDA | Entrada Therapeutics Inc | Stock-Other | 0.49% | -0.18% | — | |
| 25 | CELC | Celcuity Inc | Stock-Other | 0.48% | -1.04% | +58.96% | |
| 26 | GRAL | Grail Inc | Stock-Healthcare | 0.46% | +0.18% | — | |
| 27 | ROIV | Roivant Sciences Ltd. | Stock-Healthcare | 0.42% | +0.07% | — | |
| 28 | ✓ | Immatics NV | Stock-Other | 0.36% | -0.14% | — | |
| 29 | STOK | Stoke Therapeutics Inc | Stock-Other | 0.34% | -0.07% | — | |
| 30 | CERS | Cerus CORP | Stock-Other | 0.30% | -0.01% | -0.65% | |
| 31 | PCVX | Vaxcyte Inc | Stock-Other | 0.27% | — | +1211.01% | |
| 32 | GLUE | Monte Rosa Therapeutics Inc | Stock-Other | 0.25% | +0.12% | — | |
| 33 | CRSP | CRISPR Therapeutics AG | Stock-Healthcare | 0.25% | — | -49.99% | |
| 34 | AKRO | Akero Therapeutics Inc | Stock-Other | 0.25% | — | -49.98% | |
| 35 | SERA | Sera Prognostics Inc-a | Stock-Other | 0.22% | -0.01% | +1.17% | |
| 36 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 0.20% | -0.15% | EXIT | |
| 37 | NGNE | Neurogene Inc | Stock-Other | 0.19% | +0.05% | +120.36% | |
| 38 | IDYA | Ideaya Biosciences Inc | Stock-Other | 0.19% | +0.18% | — | |
| 39 | VRNA | Verona Pharma PLC - Adr | Stock-Other | 0.16% | — | — | |
| 40 | CADL | Candel Therapeutics Inc | Stock-Other | 0.15% | — | -18.27% | |
| 41 | PRAX | Praxis Precision Medicines I | Stock-Other | 0.14% | -0.30% | — | |
| 42 | TSVT* | 2seventy Bio Inc | Stock-Other | 0.14% | — | — | |
| 43 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 0.13% | -0.01% | -65.04% | |
| 44 | BCAX | Bicara Therapeutics Inc | Stock-Other | 0.12% | — | — | |
| 45 | IONS | Ionis Pharmaceuticals Inc | Stock-Healthcare | 0.12% | -0.07% | — | |
| 46 | DBVT | Dbv Technologies Sa-spon Adr | Stock-Other | 0.11% | -0.06% | — | |
| 47 | ALMS | Alumis Inc | Stock-Other | 0.11% | +0.03% | — | |
| 48 | ✓ | Merus N V | Stock-Other | 0.10% | — | -50.33% | |
| 49 | PRLD | Prelude Therapeutics Inc | Stock-Other | 0.09% | +0.07% | — | |
| 50 | ✓ | Verve Therapeutics Inc | Stock-Other | 0.09% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | ONC | Beone Medicines Ltd-adr | +8.9% | -7.69% | Trim |
| 2 | INCY | Incyte CORP | +8.8% | +0.00% | Trim |
| 3 | MDGL | Madrigal Pharmaceuticals Inc | +6.6% | — | Add |
| 4 | INSM | Insmed Inc | +4.3% | +7.46% | Add |
| 5 | ACAD | Acadia Pharmaceuticals Inc | +3.4% | — | Add |
| 6 | RVMD | Revolution Medicines Inc | +3.1% | — | Add |
| 7 | RYTM | Rhythm Pharmaceuticals Inc | +3% | -7.89% | Add |
| 8 | ALKS | Alkermes plc | +1.5% | +7.21% | Add |
| 9 | EWTX | Edgewise Therapeutics Inc | +1.5% | — | Add |
| 10 | KYMR | Kymera Therapeutics Inc | +1.4% | — | Add |
| 11 | REPL | Replimune Group Inc | +1.2% | — | Add |
| 12 | INSM 0.75 06-01-28Bond | Insmed Inc | +0.9% | — | Add |
| 13 | DNLI | Denali Therapeutics Inc | +0.5% | — | Add |
| 14 | RARE | Ultragenyx Pharmaceutical In | +0.4% | — | Add |
| 15 | IMCR | Immunocore Holdings Plc-adr | +0.3% | +53.28% | Trim |
| 16 | AKRO | Akero Therapeutics Inc | +0.2% | -49.98% | Add |
| 17 | NRIX | Nurix Therapeutics Inc | +0.2% | — | Add |
| 18 | 260 | Centessa Pharmaceuticals-adr | +0.2% | — | Add |
| 19 | ✓ | Immatics NV | +0.1% | — | Add |
| 20 | XENE | Xenon Pharmaceuticals Inc | +0.1% | -65.04% | Trim |
| 21 | TARA | Protara Therapeutic Inc | 0% | — | Add |
| 22 | CERS | Cerus CORP | -0.1% | -0.65% | Add |
| 23 | DSGN | Design Therapeutics Inc | -0.1% | — | Add |
| 24 | ✓ | Merus N V | -0.1% | -50.33% | Trim |
| 25 | OPTEY | Opthea Ltd-spon Adr | -0.1% | -3.97% | Trim |
| 26 | ✓ | Verve Therapeutics Inc | -0.3% | — | Add |
| 27 | ABCL | Abcellera Biologics Inc | -0.3% | — | Add |
| 28 | ARGX | Argenx Se - Adr | -1% | -30.51% | Trim |
| 29 | 1K0 | Igm Biosciences Inc | -1.1% | +0.02% | Add |
| 30 | PRLD | Prelude Therapeutics Inc | -1.2% | — | Unchanged |
| 31 | KOD | Kodiak Sciences Inc | -5.2% | — | Add |
| 32 | SGENUSD | Seagen Inc | — | EXIT | Sold out |
| 33 | BMRN | Biomarin Pharmaceutical Inc | — | EXIT | Sold out |
| 34 | SMMT | Summit Therapeutics Inc | — | NEW | New buy |
| 35 | ASND | Ascendis Pharma A/S | — | EXIT | Sold out |
| 36 | NVTA1EUR | Invitae CORP | — | EXIT | Sold out |
| 37 | MRTXEUR | Mirati Therapeutics Inc | — | EXIT | Sold out |
| 38 | BCRX | Biocryst Pharmaceuticals Inc | — | EXIT | Sold out |
| 39 | APLSUSD | Apellis Pharmaceuticals Inc | — | EXIT | Sold out |
| 40 | HRTX | Heron Therapeutics Inc | — | EXIT | Sold out |
| 41 | ✓ | Amarin Corp PLC | — | EXIT | Sold out |
| 42 | GBTUSD | Global Blood Therapeutics In | — | EXIT | Sold out |
| 43 | PACB | Pacific Biosciences Of Calif | — | EXIT | Sold out |
| 44 | IMVT | Immunovant Inc | — | NEW | New buy |
| 45 | BCYC | Bicycle Therapeutics Plc-adr | — | NEW | New buy |
| 46 | ✓ | Veralto CORP | — | EXIT | Sold out |
| 47 | ✓ | Talis Biomedical CORP | — | EXIT | Sold out |
| 48 | ✓ | — | EXIT | Sold out | |
| 49 | ✓ | Instil Bio, Inc. | — | EXIT | Sold out |
| 50 | LEGN | Legend Biotech Corp-adr | — | EXIT | Sold out |
According to official SEC Form 13F filings, Baker Bros. Advisors LP reported a total U.S. public equity portfolio value of $20.0B across 89 disclosed positions in Q1 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Top New Position Initiated
SMMT
市值: $471.2M
Top Position Liquidated / Trimmed
SGENUSD
前期市值: $7.5B
During Q1 2025, Baker Bros. Advisors LP's top holdings by market value included ONC (26.5%)、INCY (20.6%)、ACAD (7.9%). The largest single position, ONC, represented 26.5% of total portfolio value.
In Q1 2025, Baker Bros. Advisors LP made 177 total portfolio adjustments, initiating 58 new buys, adding to 23 positions, trimming 7 holdings, and fully liquidating 89 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.